Wendy Chung
Clinical Genetics (M.D.) · Boston, MANPI 1972578540
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (47.0%), consulting fees and travel and lodging — rather than concentrated in one kind of arrangement. 11 manufacturers reported payments, led by Novartis Gene Therapies, Inc. (fka Avexis, Inc.) at 24.2% of the total. Reporting peaked in 2019 at $13,090 and has fallen 72.9% since, to $3,549 in 2025. Among clinical genetics (m.d.) clinicians in MA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 56 payments — averaging $668.51 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novartis Gene Therapies, Inc. (fka Avexis, Inc.)$9K
- Biomarin Pharmaceutical Inc.$6K
- Acadia Pharmaceuticals Inc$5K
- Illumina, Inc.$4K
- Sanofi$3K
- Merck$3K
- plus $7K from 5 others
Across 64 payments — averaging $6853.27 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Rhythm Pharmaceuticals, Inc.$330K
- Regeneron$76K
- PTC Therapeutics, Inc.$33K
What the payments were for
- Consulting fees$10,32028%
- Speaking & faculty fees$17,60247%
- Travel & lodging$6,01116%
- Food & beverage$6062%
- Education$2,8978%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novartis Gene Therapies, Inc. (fka Avexis, Inc.) | 17 | $9,077 |
| Biomarin Pharmaceutical Inc. | 17 | $6,135 |
| Acadia Pharmaceuticals Inc | 1 | $5,400 |
| Illumina, Inc. | 3 | $3,541 |
| Sanofi | 3 | $3,479 |
| Merck | 1 | $2,925 |
| Pfizer | 1 | $1,800 |
| Rhythm Pharmaceuticals, Inc. | 2 | $1,575 |
| GSK | 9 | $1,511 |
| Sarepta Therapeutics, Inc. | 1 | $1,485 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $510 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- VOXZOGO 1.2mg$5,907
- NUPLAZID$5,400
- ZOLGENSMA$3,897
- Genetic Disease Testing$3,541
- VPRIV$510
How this compares
$37,437 in reported general payments places this provider in the 90th percentile of 33 clinical genetics (m.d.) providers in Massachusetts.
See all clinical genetics (m.d.) providers in Massachusetts →
Other clinical genetics (m.d.) in Boston
- Gerald CoxBoston$475K
- Stephanie SacharowBoston$80K
- Anatalia LabilloyBoston$11K
- Amy KritzerBoston$10K
- Edward NeilanBoston$9K
- Jonathan PickerBoston$8K
- Ingrid HolmBoston$8K
- Huma RanaBoston$5K
- Olaf BodamerBoston$5K
- Brian SkotkoBoston$2K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.